Answers are grounded in this paper and cite their sources.
Although induction chemotherapy (IC) in combination with concurrent chemoradiotherapy constitutes the standard treatment for locally advanced nasopharyngeal carcinoma (LANPC), the optimal number of IC cycles remains undetermined. The 9th edition staging system provides a refined risk stratification framework. We aimed to develop a prognostic tool to stratify patients with LANPC and define the optimal number of IC cycles for distinct risk groups based on new staging. We analyzed 1216 patients with LANPC treated with IC and employed propensity score matching to minimize bias. Progression-free survival (PFS) was the primary endpoint, analyzed using Kaplan-Meier curves. A recursive partitioning analysis (RPA) model was developed and validated for risk stratification. Survival outcomes and toxicities were compared across IC cycle groups. After a median follow-up of 56 months, 2- and 3-cycle IC yielded greater improvements in PFS compared with 4-cycle IC (p < 0.001). The RPA model incorporated 9th edition staging, pretreatment EBV DNA, and IC response, stratifying patients into three risk categories. For low-risk patients, 2- and 3-cycle IC yielded comparable PFS, both superior to 4-cycle IC (p < 0.001). In intermediate-risk patients, significantly higher 5-year PFS was achieved with 2-cycle IC than with 3- (73.4% vs. 56.2%, p = 0.014) or 4-cycle IC (73.4% vs. 47.5%, p < 0.001). High-risk patients benefited more from 3-cycle versus 2- (47.5% vs. 31.7%; p = 0.038) or 4-cycle IC (47.5% vs. 36.2%; p = 0.039). Overall, the RPA-based model effectively stratified risk, guiding individualized IC cycle selection. Balancing toxicity and efficacy, 2-cycle IC is optimal for the low- and intermediate-risk groups, while 3-cycle IC is preferred for the high-risk group.
No takes yet. Share an insight, caveat, or question.
Lin et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: